BlueCross BlueShield of Tennessee Medical Policy Manual

Intravenous Immune Globulin (IVIG) Therapy

DESCRIPTION

Intravenous immune globulin, (i.e., IGIV or IVIG) is used to provide passive immunity or to alter the immune response by increasing the individual's antibody titer and antigen-antibody reaction potential. Five major classes of immunoglobulin proteins exist in human serum and other body fluids. The five types are: IgA, IgD, IgE, IgG and IgM.

Gamma globulins are specialized proteins (antibodies) made by the body's immune system. Each antibody is shaped to interact with a specific target molecule found on the surface of bacteria, viruses or other infectious agents. Whenever antibodies react with their targets, the immune system may be activated to protect the body against that target. In diseases like hypogammaglobulinemia and chronic lymphocytic leukemia, the body does not make enough gamma globulin to protect against infection. In diseases like dermatomyositis the body produces abnormal gamma globulins that are shaped to interact with "targets" inside the body itself. Immune globulin is an antibody-containing solution obtained from the pooled plasma of healthy blood donors.

Examples of preparations of intravenous immune globulins are: Carimune NF, Gamimune, Gammagard S/D, Gamunex, Flebogamma, Gammar-P, Iveegam, Panglobulin, Polygam S/D, Sandoglobulin, Privigen and Venoglobulin.

REFER TO DECISION SUPPORT TREE

POLICY

Human intravenous immune globulin therapy for the treatment of primary immunodeficiencies (e.g. congenital agammaglobulinemia [X-linked agammaglobulinemia], hypogammaglobulinemia, common variable immunodeficiency, X-linked immunodeficiency with hyperimmunoglobulin M, severe combined immunodeficiency [SCID], Wiskott-Aldrich syndrome) is considered medically necessary.

Human intravenous immune globulin therapy as a treatment adjunct when administered with aspirin for Kawasaki disease is considered medically necessary.

Human intravenous immune globulin therapy as a treatment adjunct for the prevention of recurrent bacterial infections associated with B-cell chronic lymphocytic leukemia (CLL) is considered medically necessary.

Human intravenous immune globulin therapy as a treatment adjunct to prevent the risk of acute graft-versus-host disease is considered medically necessary if the medical appropriateness criteria are met. (See Medical Appropriateness below.)

Human intravenous immune globulin therapy for the treatment of idiopathic thrombocytopenic purpura (ITP) when a rise in platelet count is required (e.g., prior to surgery, to control excessive bleeding, to defer or avoid a splenectomy, or to prevent bleeding post-splenectomy) is considered medically necessary.

Human intravenous immune globulin therapy for the prevention of serious bacterial infections associated with pediatric human immunodeficiency virus (HIV) or Aids-related complex (ARC) is considered medically necessary..

Human intravenous immune globulin therapy for the treatment of acute Guillain-Barré syndrome is considered medically necessary if the medical appropriateness criteria are met. (See Medical Appropriateness below.)

Human intravenous immune globulin therapy for the treatment of dermatomyositis as second-line treatment agent is considered medically necessary if the medical appropriateness criteria are met. (See Medical Appropriateness below.)

Human intravenous immune globulin therapy for the treatment of relapsing-remitting multiple sclerosis as a second-line treatment agent is considered medically necessary.

Human intravenous immune globulin therapy for prophylaxis and treatment adjunct of infections in neonates is considered medically necessary.

Human intravenous immune globulin therapy for the treatment of chronic parvovirus B19 infection and severe anemia secondary to bone marrow suppression is considered medically necessary.

Human intravenous immune globulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathies is considered medically necessary.

Human intravenous immune globulin therapy for the treatment of multifocal motor neuropathy (MMN) as a second-line agent is considered medically necessary.

Human intravenous immune globulin therapy for the treatment of Lambert-Eaton myasthenic syndrome is considered medically necessary.

Human intravenous immune globulin therapy for the treatment of hyperimmunoglobulinemia E syndrome is considered medically necessary.

Human intravenous immune globulin therapy for the treatment of a solid organ transplant is considered medically necessary if the medical appropriateness criteria are met. (See Medical Appropriateness below.)

Human intravenous immune globulin therapy for the treatment of other conditions/diseases  including, but not limited to, the following is considered investigational: (See Applicable Tennessee State Mandate Requirements below.)

  • Alopecia universalis

  • Myasthenia gravis

  • Anemia

  • Myocarditis

  • Antenatal and neonatal thrombocytopenia

  • Myositis

  • Antiphospholipid antibody syndrome (APS)

  • Neonatal jaundice

  • Aplasia, pure red cell

  • Neuropathy

  • Asthma

  • Nodular pemphigoid

  • Autoimmune neutropenia

  • Ocular cicatricial pemphigoid

  • Behçet's syndrome

  • Otitis media

  • Bullous pemphigoid

  • Paraneoplastic pemphigus

  • Burns

  • Paraneoplastic visual loss

  • Cardiac transplant

  • Pemphigus foliaceus

  • Chronic fatigue syndrome

  • Pemphigus gestationis

  • Clostridium induced colitis

  • Pemphigus vulgaris

  • Crohn's disease

  • Polymyositis

  • Cutaneous polyarteritis nodosa

  • Post transplant lymphoproliferative disorder

  • Cystic fibrosis

  • Posttransfusion purpura

  • Diabetic amyotrophy

  • Pyoderma gangrenous

  • Encephalomyelitis - acute, disseminated

  • Recurrent fetal loss

  • Epidermolysis bullosa acquisita

  • Renal transplant

  • Epilepsy

  • Respiratory syncytial virus

  • Epstein-Barr induced cerebellar ataxia

  • Rheumatoid arthritis

  • Hematopoietic stem cell recipients

  • Stevens-Johnson syndrome

  • Hemolytic uremic syndrome

  • Stiff man syndrome

  • Hemophagocytic syndrome

  • Still's disease

  • Hemophilia

  • Systemic lupus erythematosus (SLE)

  • Hopkins' syndrome

  • Systemic vasculitis

  • In Vitro fertilization

  • Nonimmune thrombocytopenia

  • Infection prophylaxis

  • Quinine-induced thrombocytopenia

  • Isaac's syndrome

  • Refractory to platelet transfusion

  • Juvenile rheumatoid arthritis

  • Septic thrombocytopenia

  • Leukocytoclastic vasculitis

  • Thrombotic thrombocytopenic purpura

  • Linear immunoglobulin - A disease

  • Toxic shock syndrome

  • Lysinuric protein intolerance

  • Uveitis

  • Malaria

  • Von Willebrand's syndrome

  • Multiple Myeloma

  • Wegener's granulomatosis

See also:

MEDICAL APPROPRIATENESS

Human intravenous immune globulin therapy as a treatment adjunct to prevent the risk of acute graft-versus-host disease (i.e., GVHF) is considered medically appropriate for individuals who meet all of the following criteria:

Human intravenous immune globulin therapy for the treatment of acute Guillain-Barré syndrome is considered medically appropriate for individuals who meet all of the following criteria:

Human intravenous immune globulin therapy for the treatment of dermatomyositis as second-line treatment agent is considered medically appropriate for individuals who meet any of the following criteria:

Human intravenous immune globulin therapy for the treatment of a solid organ transplant is considered medically appropriate if any of the medical appropriateness criteria are met.

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

Tennessee State law requires coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is relative to life-threatening illnesses, such as cancer, AIDS, and coronary heart disease and recognized in one of the standard reference compendia (As defined in the statute:  The United States Pharmacopoeia Drug Information, The American Medical Association Drug Evaluations, & The American Hospital Formulary Service Drug Information) or in the medical literature. This law is applicable to all fully insured members. The law is not applicable to self-funded accounts.

ADDITIONAL INFORMATION  

For appropriate dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., The American Hospital Formulary Service Drug Information).

Severe thrombocytopenia is defined as a platelet count less than 20,000 / µL.

No controlled studies were found in published literature that validate the use of intravenous immune globulin (IVIG) for the prevention or treatment of other conditions/diseases.

SOURCES

BlueCross BlueShield Association. Medical Policy Reference Manual. (2:2006). Intravenous immune globulin therapy (8.01.05). Retrieved December 18, 2007 from BlueWeb.

CIGNA Government Services. Medicare Part B Carrier - Tennessee Local Coverage Determination. (2008, January). LCD for intravenous immunoglobulin (IVIG) (L6593). Retrieved December 29, 2007 from http://www.cms.hhs.gov/mcd/viewlcd.asp?lcd_id=6593&lcd_version=34&show=all

Complete Guide to Medicare Coverage Issues [Computer software]. (2007, November). Coverage of intravenous immune globulin for treatment of primary immune deficiency disease in the home (50.6, p. 4-194). St. Anthony Publishing.

Complete Guide to Medicare Coverage Issues [Computer software]. (2007, November). Intravenous immune globulin for treatment of autoimmune mucocutaneous blistering diseases (NDC 250.3, p. 2-195). St. Anthony Publishing.

Intravenous immunoglobulin (IVIG). (2006, December). The Medical Letter On Drugs and Therapeutics, 48 (Issue 1249/1250), 101-103.

Lexi-Comp Online. (2008). AHFS DI. Immune globulin®. Retrieved January 11, 2008 from Lexi-Comp Online with AHFS.

MICROMEDEX Healthcare Series. Drugdex Drug Evaluation. (2008). Immune globulin intravenous (human) (system). January 11, 2008 from MICROMEDEX Healthcare Series.

U. S. Food and Drug Administration. Center for Biologics Evaluation and Research. (2007, July). Product Approval Information. Immune globulin intravenous (human) 10% liquid (Privigen).  Retrieved January 16, 2008 from http://www.fda.gov/cber/products/privigen.htm.

U. S. Food and Drug Administration. Center for Biologics Evaluation and Research. (2003, August). Product Approval Information. Immune globulin intravenous [human], 10% caprylate/chromatography purified (Gamunex®). Retrieved January 16, 2008 from http://www.fda.gov/cber/label/igivbay082703LB.pdf.

U. S. Food and Drug Administration. Center for Biologics Evaluation and Research. (2007, August). Immune globulin intravenous (IGIV) indications. Retrieved January 16, 2008 from http://www.fda.gov/cber/products/igivlist.htm.

ORIGINAL EFFECTIVE DATE:  12/4/1997

MOST RECENT REVIEW DATE:  6/14/2008

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

Pharmaceutical Decision Support Tree

Intravenous Immune Globulin (IVIG) Therapy (Carimune NF, Gamimune, Gammagard S/D, Gamunex, Flebogamma, Gammar-P, Iveegam, Panglobulin, Polygam S/D, Privigen, Sandoglobulin and Venoglobulin)

  1. Is the requested medication being used to treat alopecia universalis, anemia, antenatal and neonatal thrombocytopenia, antiphospholipid antibody syndrome (APS), aplasia, pure red cell, asthma, Behçet's syndrome, bullous pemphigoid, burns, cardiac transplant, chronic fatigue syndrome, clostridium induced colitis, Crohn's disease, cutaneous polyarteritis nodosa, cystic fibrosis, diabetic amyotrophy, encephalomyelitis - acute, disseminated, epidermolysis bullosa acquisita, epilepsy, Epstein-Barr induced cerebellar ataxia, hemolytic uremic syndrome, hemophagocytic syndrome, hemophilia, hematopoietic stem cell recipients, Hopkins' syndrome, infection prophylaxis, in vitro fertilization, Isaac's syndrome, juvenile rheumatoid arthritis, linear immunoglobulin - A disease, post transplant lymphoproliferative disorder, leukocytoclastic vasculitis, lysinuric protein intolerance, malaria, multiple myeloma, myasthenia gravis, myocarditis, myositis, neonatal jaundice, neuropathy, autoimmune neutropenia, nodular pemphigoid, ocular cicatricial pemphigoid, otitis media, paraneoplastic visual loss, paraneoplastic pemphigus, pemphigus foliaceus, pemphigus gestationis, pemphigus vulgaris, polymyositis, posttransfusion purpura, pyoderma gangrenous, renal transplant, respiratory syncytial virus, rheumatoid arthritis, recurrent fetal loss, Stevens-Johnson syndrome, Stiff man syndrome, Still's disease, systemic lupus erythematosus (SLE), systemic vasculitis, thrombocytopenia refractory to platelet transfusion, thrombotic thrombocytopenic purpura, nonimmune thrombocytopenia, septic thrombocytopenia, quinine-induced thrombocytopenia, toxic shock syndrome, uveitis, Von Willebrand's syndrome or Wegener's granulomatosis?

If yes, this does not meet medical necessity and/or medical appropriateness criteria

If no, go to question #2

  1. Is IVIG being used for the treatment of primary immunodeficiencies (e.g. congenital agammaglobulinemia [X-linked agammaglobulinemia], hypogammaglobulinemia, common variable immunodeficiency, X-linked immunodeficiency with hyperimmunoglobulin M, severe combined immunodeficiency [SCID], Wiskott-Aldrich syndrome)?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #3

  1. Is IVIG being administered with aspirin as a treatment adjunct for Kawasaki disease?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #4

  1. Is IVIG being used as a treatment adjunct for the prevention of recurrent bacterial infections associated with B-cell chronic lymphocytic leukemia (CLL)?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #5

  1. Is IVIG being used as a treatment adjunct for an individual of 20 years of age or older, and within 100 days post bone marrow transplantation, to prevent the risk of acute graft-versus-host disease associated interstitial pneumonia (e.g., infectious or idiopathic) or infections (e.g., varicella-zoster virus infection, recurrent bacterial infection) after bone marrow transplantation (BMT)?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #6

  1. Does the individual have a diagnosis of idiopathic thrombocytopenic purpura (ITP) and is the agent being used for a rapid rise in platelet count (e.g., prior to surgery, to control excessive bleeding, to defer or avoid a splenectomy, or to prevent bleeding post-splenectomy)?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #7

  1. Is IVIG being used to reduce the risk of serious bacterial infections in pediatrics' with a diagnosis of human immunodeficiency virus (HIV) or aids-related complex (ARC)?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #8

  1. Is IVIG being used in the treatment of adults (18 years of age or older) so severely impaired by Guillain-Barré syndrome they require assistance to walk and the disorder was diagnosed within the first two weeks of illness?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #9

  1. Is IVIG being used as second-line treatment agent when individuals are corticosteroid-resistant, or corticosteroids are contraindicated in the treatment of dermatomyositis?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #10

  1. Is IVIG being used as a second-line treatment agent for relapsing-remitting multiple sclerosis?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #11

  1. Is IVIG being used as prophylaxis, or as a treatment adjunct, for infections in neonates?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #12

  1. Is IVIG being used in the treatment of chronic parvovirus B19 infection or severe anemia secondary to bone marrow suppression?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #13

  1. Is IVIG to be administered as a treatment of chronic inflammatory demyelinating polyneuropathies?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #14

  1. Is IVIG being used as a second-line treatment of multifocal motor neuropathy (MMN)?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #15

  1. Is IVIG being used as a treatment of Lambert-Eaton myasthenic syndrome?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #16

  1. Is IVIG to be administered as a treatment of hyperimmunoglobulinemia E syndrome?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, go to question #17

  1. Is IVIG being requested for the treatment of a solid organ transplant that meets any of the following?

If yes, this satisfies medical necessity and medical appropriateness criteria

If no, this does not meet medical necessity and/or medical appropriateness criteria

This document has been classified as public information.